sec filing
OV
NASDAQ · OVID
Ovid Therapeutics Inc.
Healthcare · Biotechnology
$2.80
Up+$0.06 (+2.19%)
Updated Aug 22, 2026, 3:28 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 117.35M
- P/E ratio
- -0.06
- Dividend yield
- 0.00%
- 52-week range
- $0.89 – $3.11
- Volume
- 1.33M
- Avg. volume
- 2.89M
Price performance
OVID price history
1M range · 21 trading sessions · Daily adjusted prices
OVID closed at $2.80 after 21 trading sessions, up 20.17% for the selected period.
- Last close
- $2.80
- Period change
- +20.17%
- Period low
- $2.22
- Period high
- $2.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.76 | $2.83 | $2.71 | $2.80 | 1.33M |
| Aug 20, 2026 | $2.88 | $2.93 | $2.72 | $2.74 | 1.15M |
| Aug 19, 2026 | $2.90 | $2.95 | $2.84 | $2.93 | 2.88M |
| Aug 18, 2026 | $2.87 | $2.905 | $2.795 | $2.84 | 1.94M |
| Aug 17, 2026 | $2.83 | $2.92 | $2.80 | $2.89 | 1.75M |
| Aug 14, 2026 | $2.80 | $2.87 | $2.745 | $2.83 | 1.24M |
| Aug 13, 2026 | $2.65 | $2.875 | $2.62 | $2.80 | 2.24M |
| Aug 12, 2026 | $2.44 | $2.645 | $2.43 | $2.62 | 931.47K |
| Aug 11, 2026 | $2.62 | $2.65 | $2.525 | $2.58 | 903.2K |
| Aug 10, 2026 | $2.59 | $2.62 | $2.53 | $2.62 | 1.25M |
| Aug 7, 2026 | $2.69 | $2.69 | $2.60 | $2.63 | 919.7K |
| Aug 6, 2026 | $2.62 | $2.685 | $2.585 | $2.65 | 1.29M |
| Aug 5, 2026 | $2.52 | $2.68 | $2.49 | $2.62 | 2.25M |
| Aug 4, 2026 | $2.33 | $2.555 | $2.33 | $2.54 | 1.67M |
| Aug 3, 2026 | $2.222 | $2.36 | $2.222 | $2.33 | 1.68M |
| Jul 31, 2026 | $2.36 | $2.36 | $2.20 | $2.22 | 1.75M |
| Jul 30, 2026 | $2.30 | $2.375 | $2.275 | $2.37 | 1.29M |
| Jul 29, 2026 | $2.35 | $2.40 | $2.255 | $2.29 | 648.34K |
| Jul 28, 2026 | $2.42 | $2.42 | $2.24 | $2.36 | 1.35M |
| Jul 27, 2026 | $2.35 | $2.485 | $2.31 | $2.35 | 1.05M |
| Jul 24, 2026 | $2.40 | $2.40 | $2.31 | $2.33 | 984.98K |
Latest OVID news
The latest Smart Investors Daily articles mentioning OVID.
Stock researchResearch & News · Competitors
Loading stock research…

